Pharmacoeconomic Aspects Of Drugs Used In Migraine Patients

Abstract

Migraine is a chronic, disabling neurological disorder characterized by recurrent newlineepisodes of moderate to severe headache, often accompanied by symptoms such as newlinenausea, photophobia, and phonophobia. It affects over one billion people globally and newlinerepresents a significant public health concern, particularly among women and individuals newlinein their most productive years. In India alone, more than 213 million individuals suffer newlinefrom migraine, contributing to considerable healthcare utilization and societal burden. newlineThe condition not only diminishes quality of life but also leads to substantial economic newlinecosts due to frequent medical consultations, medication use, and productivity losses from newlinework absenteeism and reduced efficiency. Despite the availability of a wide range of newlinepharmacological options, including acute and preventive treatments, the choice of newlinetherapy often lacks a structured evaluation of economic outcomes. With rising healthcare newlinecosts and resource constraints, there is a growing need to assess the pharmacoeconomic newlineimpact of migraine therapies. Understanding the cost-effectiveness of different treatment newlineoptions and their implications on healthcare systems and societal productivity is crucial newlinefor informed decision-making and the development of efficient, sustainable migraine newlinemanagement strategies. newlineThe aim of the present study is to evaluate the pharmacoeconomic impact of drugs used newlinein the management of migraine from both societal and healthcare system perspectives. newlineThe objectives include assessing the cost-effectiveness of various pharmacological newlinetreatments by considering not only direct medical costs but also indirect costs such as newlineproductivity loss. The study seeks to compare the economic outcomes of different drug newlinetherapies, encompassing both acute and preventive treatments, while analyzing patterns newlineof healthcare resource utilization, including hospitalizations, outpatient visits, and newlinemedication usage. It also aims to examine how these therapies influence clinical newlineoutcomes and quality of life among migraine